# TXA127 in Enhancement of Engraftment in Adult Double Cord Blood Transplantation

> **NCT01300611** · PHASE1 · TERMINATED · sponsor: **Tarix Pharmaceuticals** · enrollment: 20 (estimated)

## Conditions studied

- Double Cord Blood Transplant
- Acute Myelogenous Leukemia
- Myelodysplastic Syndrome
- Myelofibrosis
- Acute Lymphoblastic Leukemia
- Chronic Myelocytic Leukemia
- Non Hodgkins Lymphoma
- Hodgkins Lymphoma
- Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** TXA127 300 mcg/kg/day
- **DRUG:** TXA127 1000 mcg/kg/day

## Key facts

- **NCT ID:** NCT01300611
- **Lead sponsor:** Tarix Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-01
- **Primary completion:** 2020-12
- **Final completion:** 2020-12
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2020-12-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01300611

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01300611, "TXA127 in Enhancement of Engraftment in Adult Double Cord Blood Transplantation". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01300611. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*